commit 66dd5b47dd5fb6664db1f390f54c2eb8e0fe6a30
parent 9ac737dd6b876ef83ea35f384206a2a56993c184
Author: Beau Hilton <beau.hilton@vumc.org>
Date: Sun, 22 Aug 2021 16:12:31 -0500
ngs
Diffstat:
1 file changed, 11 insertions(+), 2 deletions(-)
diff --git a/posts/mr-2021.md b/posts/mr-2021.md
@@ -87,6 +87,12 @@ Details modified, generalized, and otherwise fudged to be HIPAA-compliant.
- pelvic mass bx: smooth muscle
- BMBx: hypercellular >90%, no blasts, +trilineage atypica > myeloid, MF-1 fibrosis.
- JAK2 -ve, BCR/ABL -ve
+- NGS
+ - BRAF 5% (MGUS, MM, hairy cell, hystiocytic/dendritic cell, solid tumors, therapy-related myeloid neoplasms)
+ - KRAS 39% (MDS, AML, MDS/MPN inc CMML and JMML)
+ - BCOR 49% (?, possibly germline since allele fraction ~50%)
+ - BCORL1 48% (ditto)
+ - EZH2 93% (?, likely germline w loss of heterozygosity)
---
@@ -98,12 +104,15 @@ The big idea, and a few finer points.
### Cairo-Bishop classification system
-(From [Chapter 4](https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter4.pdf)
+(Most of the following derived from
+[Chapter 4](https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter4.pdf)
of the American Society of Nephrology online
-[Onco-Nephrology curriculum](https://www.asn-online.org/education/distancelearning/curricula/onco/))
+[Onco-Nephrology curriculum](https://www.asn-online.org/education/distancelearning/curricula/onco/),
+which is good and great.)
### Laboratory TLS
+Definition:
Chemotherapy plus the two or more of the following
within 3d before or 7d after initiation
(so doesn't account for the spontaneous TLS seen in our patient).
